BACKGROUND AND PURPOSE: Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. Evodiamine is structurally different from all known TRPV1 activators, and has significant clinical potential as a thermogenic agent. Nevertheless, the molecular bases for its actions are still poorly understood. EXPERIMENTAL APPROACH: To investigate the structure-activity relationships of evodiamine, the natural racemate was resolved, and a series of 23 synthetic analogues was prepared, using as the end point the intracellular Ca(2+) elevation in HEK-293 cells stably overexpressing either the human or the rat recombinant TRPV1. KEY RESULTS: S-(+) evodiamine was more efficacious and potent than R-(-) evodiamine, and a new potent lead (Evo30) was identified, more potent than the reference TRPV1 agonist, capsaicin. In general, potency and efficacy correlated with the lipophilicity of the analogues. Like other TRPV1 agonists, several synthetic analogues could efficiently desensitize TRPV1 to activation by capsaicin. CONCLUSIONS AND IMPLICATIONS: Evodiamine qualifies as structurally unique lead structure to develop new potent TRPV1 agonists/desensitizers.
BACKGROUND AND PURPOSE:Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. Evodiamine is structurally different from all known TRPV1 activators, and has significant clinical potential as a thermogenic agent. Nevertheless, the molecular bases for its actions are still poorly understood. EXPERIMENTAL APPROACH: To investigate the structure-activity relationships of evodiamine, the natural racemate was resolved, and a series of 23 synthetic analogues was prepared, using as the end point the intracellular Ca(2+) elevation in HEK-293 cells stably overexpressing either the human or the rat recombinant TRPV1. KEY RESULTS:S-(+) evodiamine was more efficacious and potent than R-(-) evodiamine, and a new potent lead (Evo30) was identified, more potent than the reference TRPV1 agonist, capsaicin. In general, potency and efficacy correlated with the lipophilicity of the analogues. Like other TRPV1 agonists, several synthetic analogues could efficiently desensitize TRPV1 to activation by capsaicin. CONCLUSIONS AND IMPLICATIONS: Evodiamine qualifies as structurally unique lead structure to develop new potent TRPV1 agonists/desensitizers.
Authors: Kumar Changani; Sarah Hotee; Simon Campbell; Kashmira Pindoria; Laura Dinnewell; Paula Saklatvala; Sally-Anne Thompson; Diane Coe; Keith Biggadike; Giovanni Vitulli; Marion Lines; Albert Busza; Jane Denyer Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: Narender R Gavva; Lana Klionsky; Yusheng Qu; Licheng Shi; Rami Tamir; Steve Edenson; T J Zhang; Vellarkad N Viswanadhan; Attila Toth; Larry V Pearce; Todd W Vanderah; Frank Porreca; Peter M Blumberg; Jack Lile; Yax Sun; Ken Wild; Jean-Claude Louis; James J S Treanor Journal: J Biol Chem Date: 2004-03-02 Impact factor: 5.157
Authors: Karl S A Vallin; Karin J Sterky; Eva Nyman; Jenny Bernström; Rebecka From; Christian Linde; Alexander B E Minidis; Andreas Nolting; Katja Närhi; Ellen M Santangelo; Fernando W Sehgelmeble; Daniel Sohn; Jennie Strindlund; Dirk Weigelt Journal: Bioorg Med Chem Lett Date: 2012-07-14 Impact factor: 2.823
Authors: Arthur Gomtsyan; Erol K Bayburt; Ryan Keddy; Sean C Turner; Tammie K Jinkerson; Stanley Didomenico; Richard J Perner; John R Koenig; Irene Drizin; Heath A McDonald; Carol S Surowy; Prisca Honore; Joe Mikusa; Kennan C Marsh; Jill M Wetter; Connie R Faltynek; Chih-Hung Lee Journal: Bioorg Med Chem Lett Date: 2007-05-03 Impact factor: 2.823
Authors: Jamie R Friedman; Nicholas A Nolan; Kathleen C Brown; Sarah L Miles; Austin T Akers; Kate W Colclough; Jessica M Seidler; John M Rimoldi; Monica A Valentovic; Piyali Dasgupta Journal: J Pharmacol Exp Ther Date: 2017-12-15 Impact factor: 4.030